ArriVent BioPharma Inc IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on ArriVent BioPharma Inc, and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| ArriVent BioPharma Inc | AVBP - NASDAQ |
$17.00-$19.00 | $18.00 | $24.00 | 9.7 million | 1/26/2024 |
| Goldman Sachs, Jefferies, Citigroup | ||||||
Co-Manager(s): LifeSci Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-01-05 Terms Added 2024-01-22 | ||||||
ArriVent BioPharma Inc Quote & Chart - Click for current quote - AVBP
IPO Boutique aggregates information on public companies and private companies, such as "AVBP" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About ArriVent BioPharma Inc (adapted from ArriVent BioPharma Inc prospectus):
They are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AVBP" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.